---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-032096"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T21:54:00.089650+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CAMP4 Therapeutics reports Q1 net loss $18.3M; files first CMP-002 regulatory submission in Australia

## Summary
- Cash and equivalents $99.2M as of 3/31/26, down from $109.5M; runway expected into 2028.
- Net loss $18.3M vs $12.4M YoY, including $6.2M non-cash loss on derivative tranche liability.
- Submitted first regulatory filing for CMP-002 (SYNGAP1) in Australia; global Phase 1/2 trial anticipated in 2H 2026.
- EMA granted orphan designation for CMP-002; FDA ODD application pending.
- Appointed Michael MacLean to Board of Directors.

## SEC filing metadata
- accession: 0001628280-26-032096
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000162828026032096/0001628280-26-032096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000162828026032096/camp-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-032096
- JSON: https://secwatch.observer/filing/0001628280-26-032096.json
- Plain text: https://secwatch.observer/filing/0001628280-26-032096.txt

## Source-grounded claims
- claim_id: 1f8f5ed7abb24229012dc46cc5ec86ad6fffdaf8
  claim: Camp4 Therapeutics Corp reported the first quarter ended March 31, 2026 results: net income Net loss for the quarter ended March 31, 2026 was $18.3 million, compared to $12.4 million for the quarter ended March 3.
  evidence_excerpt: CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the first quarter ended March 31, 2026, and provided recent corporate highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1736730/000162828026032096/0001628280-26-032096-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.